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ABSTRACT 
 
Many of earlier reports suggest a connection between hepatitis C virus (HCV) infection and type2 diabetes (T2D). 
However, the results are conflicting. The aim of our study was to investigate the seroprevalence of both HCV 
infections and hepatitis B virus (HBV) in type 2 diabetes mellitus (DM) patients in Yemen as well as the risk of 
hepatitis for development diabetes mellitus.120 patients were enrolled for this study: 50 patients with T2D, 70 with 
chronic hepatitis(29 with HCV,36 with HBV and 5 were infections with HCV and HBV) along with 50 healthy 
control. Investigated hepatitis C and B patients for blood sugar, determined hepatitis B surface antigen (HBsAg) and 
anti-HCV in both groups, measured by chromatographic and enzyme-linked immunosorbent assay(ELSIA). We 
found that in T2D-patients 7 out of 50 (14%) detected with hepatitis, 5 (10 %) of 50 T2D-patients had evidence of 
HCV infection compared to 2 (4%) with HBV. The development diabetic mellitus among 70 hepatitis C and B 
patients 8 out of 70 (11.4%), 3 HBV 36 (8.3%), 4 HCV 29 (13.7%), 1 Co-infection HBV and HCV 5 (20%) 
compared to 1 (2%) without association in 50 control adults. The antibodies levels in T2D-patients with HCV 
viremia were significantly higher than those in HBV patients. HCV viremia, sex, age, family history of diabetes and 
tobacco use was found to be difference independent risk factors for diabetes. 
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Introduction 
 
Liver is the primary site of hormone and glucose 
metabolism, and the intercommunication between liver 
and diabetes has long been recognized. The majority of 
patients with cirrhosis have glucose intolerance (60%) 
or overt diabetes mellitus (DM, 20%) [1]. In the 
Middle East, reliable data upon this subject are scant, 
however, based on the few available reports, the 
prevalence of DM is in the range of 4–14% [2,3]. This 
variation may be partly due to the use of different 
criteria for diagnosis rendering comparison between 
countries difficult. The prevalence of type 2 diabetes 
mellitus in population of Yemen, according to the 1999 
WHO was found to be 4.6% [4].  
_______________________________ 
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Hepatitis C virus (HCV) seems to increase the risk of 
incident type 2 diabetes (DM) in predisposed 
individuals [5].A linkage between type2 diabetes and 
chronic hepatitis C virus(HCV) infection, however the 
presence of additional factors such as obesity, aging or 
cirrhosis  
prevents the establishment of a definite relationship 
between these 2 conditions [6].HCV interferes with 
glucose metabolism independently of age and stage of 
liver disease, but it is during the cirrhotic stage that 
multiple factors contributing to insulin resistance may 
prevail and mask the HCV-related effect [7].A higher 
prevalence of HCV infection has been reported in 
Spain in diabetic patients (11.5%) in comparison with 
blood donors (2.5%) [8]. On the other hand, 4.2% of 
patients from a diabetes clinic in North America, were 
found to be positive for anti-HCV antibodies, 
compared with 1.6% in the control patients [9].Yemen 
near to the Middle East region, where the disease exists 
with different degrees of prevalence, from low to high 
  
Asian Pac. J. Health Sci., 2014; 1(4): 370-376                                        e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
 Thabet et al ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2014; 1(4): 370-376 
www.apjhs.com      371 
 
endemicity, and prevalence varies from 2% to 
20%[10,11]. Most studies conducted in Yemen to 
establish the prevalence of HBV (12—18.5%) have 
been undertaken in tertiary health care settings 
[10,12]and have included patients with acute or chronic 
hepatitis admitted to hospital or blood donors 
[13,14].HCV , HBV infections and diabetes mellitus 
have become major public health problems, 
approaching epidemic magnitude worldwide. In view 
of their strong association with each other and there has 
been no previous study the relationship of hepatitis C 
or B in type 2 DM patients in Yemen. The objectives 
of this study were to estimate the association rates of 
hepatitis C and B in type 2 DM patients visiting clinics 
and hospitals, and to find out the risk in hepatitis 
patients for type 2 DM. 
 
Methods 
 
One-hundred and twenty patients were  divided  into 
two comparison groups first group70  chronic hepatitis 
C and B patients, second group 50 diabetes mellitus, 
along with 50 healthy subjects were included as 
control.  The patients were hospitalized and diagnosis 
confirmed for all cases. At the same time, a 
questionnaire was used to collect information on the 
characteristics of hepatitis and diabetes patients which 
included: age, sex, khate chewing, smoking, family 
history of diabetes, surgical operation, dental operation 
and blood transfusions, which were considered as risk 
factors for diabetic and hepatitis.The diabetes patients 
strictly diagnostic under treatment by supervision 
doctors in clinical and hospitals at Taiz and Ibb city-
Yemen. Blood samples were taken in random and 
fasting states patients, plasma glucose was measured 
using spectrophotometer, (random blood glucose 
120±190mg/dl as diabetes). Venous blood sample were 
taken from hepatitis patients in random state for plasma 
glucose study. Venous blood sample were taken from 
diabetes patients for testing for hepatitis B surface 
antigen (HBsAg) by enzyme-linked immunosorbent 
assay (ELISA) (Abbott- Murex, HBsAg, Version 3.0; 
Murex Biotech Limited, Central Road, Dartford, UK)  
and testing for anti-HCV antibodies by ELISA 
(Abbott-Murex, Anti-HCV, Version 4.0, Murex 
Biotech Limited)  according to the manufacturers’ 
instructions.  
All patients were chronic carriers with excluded acute 
liver disease, liver cirrhosis and fibrosis also cancer 
patients. 
The data were expressed as the number and percent. 
Comparisons between groups were made using the 2×2 
contingency table was performed for the categorical 
variables using the chi square test. A multivariate 
logistic regression model was used to determine the 
independent effect of various factors that were 
potentially associated with the risk of hepatitis. These 
factors included sociodemographic variables (age, sex, 
family history of diabetics, tobacco use, and chewing 
khat) and clinical characteristics (hospital admission, 
dentils admission, surgical operation, blood 
transfusions and shave at barber).Statistical analyses 
were performed using SPSS software program version 
19. Test probability levels less than0.05 was considered 
to be statistically significant. 
 
Results 
Demographic and clinical characteristics of the 
study subjects 
 
Out of the120 patients identified, 50 were diabetes 
patients and 70 were hepatitis C and B virus patients 
figure (1). Diabetes patients, the baseline demographic 
and clinical characteristics of the study subjects was 
shown in tables (1) and (2) , while for hepatitis C and B 
virus  patients  was shown in tables (3) and (4). Though 
the development of diabetes mellitus among hepatitis 
virus slightly slower 11% than prevalence of hepatitis 
C and B virus among diabetic patients 14%. The major 
significant in our study was higher prevalence of HCV 
than HBV among T2D-patients.In the group of control 
subjects 2, 1 and 1out of 50 was T2D, HCV and HBV 
positive, without any association between them. 
The risk factors(demographic factors) in the tow 
comparisons groups that suggest enhances developed 
diseases in both groups that shown in tables (1) and (3), 
included  age, sex, family history of diabetes, tobacco 
use, chewing khat and clinical characteristics(data not 
showed) that mounted on questionnaire form. Some 
differences such as age in T2D- patients with HCV 
antibodies aged range ( 60-70 years) with mean (62)  
while T2D-patients without HCV infection aged range 
( 35-90 years) with mean (54) and in the second 
comparison  group, HCV patients with DM aged 
between comparisons  (42-65) with mean (49.25), 
while HCV patients with no DM aged between (23-80) 
with mean (32-42), also family history of diabetes 
expert less likely differences as in HCV patients with 
DM positive 50%, while HCV patients without DM 
40%, family history of diabetes in T2D-patients with 
HCV patients 80%, while in T2D-patients without 
HCV patients 67%  and the sex as in T2D-patients with 
HCV males 60%, while females' 40% from the subject 
whom 25 males and 25 females. Tobacco use and 
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chewing khat was high in T2D-patients with HCV 100% 
compared with HCV-patients with T2D 50 and 75%. 
 
Association between hepatitis C and B in type2 
diabetic patients (T2DM) 
  
Overall, the association between hepatitis C and B viruses  
was diagnosed in 7 out of the 50 subjects of  T2DM 
(14%), while the developing of DM in hepatitis C and B 
was 8 out of 70 subjects (11%), but compared to healthy 
control, the HCV infection was higher prevalence [5 
(71%) odds ratio(OR) = 5,44;95% confidence interval 
(CI):0.61-48.3; p = 0.09]compared to HBV infection [ 2 
(29%) OR = 2,04; 95% CI,0.179—23.0; p= 0.55] in 
T2DM. The development of DM in Co-infection hepatitis 
C and B virus was 1 out of 5 patients (20%), highest than 
mono infection B and C infections. Prevalence of DM in 
hepatitis patients was 8 out of 70 (11.4%), [3 HBV 36 
(8.3%) OR = 2,8; 95% CI,0.25—33.0; p = 0.37], 4 HCV  
[29 (13.7%) OR = 7,3; 95% CI,0.83—73.9; p = 0.03],  1 
Co-infection HBV and HCV [5 (20%) OR = 12,25; 95% 
CI,0.63—234.8; p = 0.04]table 4. In this study we found 
the significant differences between prevalence HCV and 
co-infections in T2DM patients and the strict association 
between HCV and diabetic mellitus, also we found in our 
investigation in the hospital and clinical records 
hyperglycemia more elevated in HCV patients with renal 
dialysis 10 of the70 subjects 14%, but the strong 
association was between HCV patients and hyperglycemia 
8 in 29 (28%) data not showed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Profile of the study patients and their categorization based onT2DM and Hepatitis 
Total individual  
N=170 
Type 2 diabetes 
patients N=50 
Hepatitis Virus 
Patients N=70 
Tested for HCV and HBV N=7 (14%) 
Tested and diagnosed for DM N 
=8 (11%) 
HBV patients N= 
36(51%) 
HCV patients  N= 
29(41%) 
Ant-HCV positive 
N = 5(71%) 
HBsAg positive 
N=2(29%) 
DM positive 
N=4(50%) 
DM positive N= 
3(37%) 
HCV and HBV co-infection 
patients N=5(8%) 
DM positive 
N=1(13%) 
Control N=50 
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Table 1: Demographic data in 50 T2D-patients with and without HCV and HBV infection 
 
Statistical difference between T2D patients with HCV antibodies, HBsAg and patients with no evidence for HCV, 
HBV infection 
                                      Table 2: HCV and HBV infection in T2D-patients 
 
 
 
 
 
 
 
 
 
 
Table 3 : Demographic data in 70 hepatitis patients with and without diabetes mellitus 
     Group 
 
Risk factors 
T2D-patients 
with HCV 
antibodies, n (%) 
T2D-patients 
without HCV 
infection, n (%) 
T2D-patients 
with HBsAg, n 
(%) 
T2D-patients without 
HBsAg  , n (%) 
p-Value  
HCV     HBV 
 
Age (median in 
years) 
60-70 (62) 35-90(54) 55-60(57.5) 35-90(54.7) 0.21    0.43     
Sex 
(M) 
(F )  
 
3 ( 60 %) 
2 ( 40 %) 
 
22(48.9 %) 
23(51.1 %) 
 
1 (50 % ) 
1 (50 % ) 
 
24( 50% 
24(50 %) 
 
0.31     0.60 
Family history of 
diabetes 
Yes 
No 
 
 
4(80%) 
1(20%) 
 
 
30(67 %) 
15(33) % 
 
 
2(100%) 
(0 %) 
 
 
30 (63 %) 
18 (37 %) 
 
 
0.36      0.67 
Tobacco Use 
Yes 
No 
 
5(100%) 
(0 %) 
 
13(28.2%) 
32(71,1%) 
 
1(50 %) 
1(50 %) 
 
17(35.42 %) 
31(64.58%) 
 
0.08     0.17 
Chewing  khat 
Yes 
No 
 
5(100%) 
(0 %) 
 
32(71,1%) 
13 (28.2 % 
 
1(50 %) 
1(50 %) 
 
36(75 %) 
12(25%) 
 
0.10      0.19 
Subject groups HCV Antibodies,n (%) HBsAg , n (%) 
T2D-patients 
   Total  (n = 50) 
Males (n = 25) 
Females (n =25) 
Control subjects  
   Males ( n= 32 ) 
   Females ( n= 18 )  
 
5(10%) 
3 (60%) 
2(40 %) 
 
0(0%) 
1(2%) 
 
2(4%) 
1(50%) 
1(50 %) 
 
0(0%) 
1(2%) 
p-
Value 
HCV 
HBV  
Co 
 
Co-
infection 
without 
DM n(%) 
Co-infection 
withDM,n(%) 
HBsAg 
without 
DM, n 
(%) 
 
HBsAg 
with DM, 
n (%) 
HCV 
infection, 
without 
DM, n 
(%) 
HCV 
antibodies, 
with DM, n( 
%) 
Group 
 
 
Risk factors 
0.37    
0.69   
0.77 
21-
45(31.5) 
50 17-
70(32.6) 
55-
70(63.33) 
23-
80(32.42) 
42-65(49.25) Age(mean) 
 
0.20    
0.31   
 
3(75) 
1(25) 
 
1(100) 
  (0) 
 
27( 1.8) 
6(18.1) 
 
2 (67 ) 
1 (33 ) 
 
12(48 ) 
13(52 ) 
 
3 ( 75 ) 
1 ( 25 ) 
Sex 
M 
F 
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Statistical difference between hepatitis patients with and without T2DM. 
 
Table 4:  T2D-patients  with HCV, HBV and co-infection viruses 
 
 
Discussion 
 
The prevalence of HCV infection obtained in T2D-
patients (10%) compared to HBV infection in T2D- 
patients (4%),similar to our results studies that have 
noted the prevalence of HCV infection in T2D-patients 
(3%) in Kuwait, which has a high incidence of type 2 
diabetes [12-13] Reported that the excess of DM risk 
with HCV infection in comparison to the excess risk 
observed in infected patients. The rate of seropositive 
anti-HCV is 2.8 times higher in type 2 DM patients 
than non-diabetic control and no significant difference 
was found between type 2 DM patients and the control 
group for seropositivity of HBsAg (13.5% versus 
12.4%) [15]. Data of previous literature and our study 
shows a strong association between HCV and type2 
diabetes, may be explain the association of type 2 
diabetes with HCV due to pathophysiology of HCV-
associated T2D consists of a defect in insulin secretion, 
excessive hepatic glucose production, increased hepatic 
tumor necrosis factor alpha, and insulin resistance 
Emerging evidence in animals and humans has shown 
that HCV infection induces hepatic steatosis and 
increases tumor necrosis factor-a level, both resulting 
in the development of insulin resistance and subsequent 
type 2 diabetes [16].  However, results of this study 
enhancing the role of HCV infection in the 
development of diabetes, support results from previous 
studies have shown that patients with chronic HCV 
genotype 4 infection have an increased risk to develop 
glucose abnormalities [17,18]. This study prevalence 
HCV infections patients was higher than HBV in 
T2DMwith 13.7% and 8.8% respectively. This indicate 
the role of HCV virus for induce DM. Our results are 
in agreement with those of [19] who reported the link 
that has been established between HCV infection and 
the excess risk of type 2 DM observed in comparison 
with HBV infected patients suggests a potential direct 
viral role in promoting DM risk.[20] was found the 
prevalence of type 2 diabetes as 31.5% (114 cases) out 
of 361 hepatitis C seropositive patients. 
[6]have shown the ability of insulin to lower the 
plasma glucose level in the HCV transgenic mice was 
impaired, as observed in chronic hepatitis C patients. 
0.76 
 
 
0.64    
0.99   
0.0 
 
 
(0) 
4(100) 
 
 
(0%) 
 
 
 
12(36.4) 
21(63.6) 
 
 
2(66.7%) 
1(33.30) 
 
 
10(40%) 
15(60%) 
 
 
2(50%) 
2(50%) 
Family  history                                                                     
of DM 
yes 
No 
 
0.37    
0.55   
0.77 
 
1(25%) 
3(75%) 
 
1(100) 
 
13(39.39 ) 
20(60.61) 
 
1(33 %) 
2(66.7 %) 
 
8(32%) 
17(68%) 
 
2(50%) 
2(50%) 
Tobacco use 
Yes 
No 
 
0.24    
0.33   
0.51 
 
2(50) 
2(50) 
 
1(100) 
 
24(72.73 ) 
9(27.27) 
 
2(66.67 ) 
1(33.33 ) 
 
12(48%) 
13(52%) 
 
3(75%) 
1(25%) 
Chewing  khat 
Yes 
No 
T2D-patients with Co-infection 
HCV and HBV viruses 
T2D-patients in 
HBsAg, n (%) 
T2D-patients in HCV 
antibodies,n (%) 
Subject groups 
 
 
1(20%) 
1(100%) 
0% 
 
 
3(8.3%) 
2 (67 % ) 
1 (33 % ) 
 
 
4(13.7%) 
3 (75%) 
1(25 %) 
Hepatitis C and B 
viruses 
Total  (n = 70) 
Males (n = 33) 
Females (n =37) 
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These results provide a direct experimental evidence 
for the contribution of HCV in the development of 
insulin resistance inhuman HCV infection, which 
finally leads to the development of type 2 diabetes. 
HCV infection influences the development of diabetes 
among 153 HCV-infected subjects 32 (20.9%), 
developed DM after HCV infection, eight of those 
(25.0%) followed spontaneous clearance and 24/32 
with HCV. Other earlier study [13] reported three 
individuals with HCV developed post-IFN treatment 
DM and were included in the HCV control group 
without DM. The demographic factors questionnaire in 
our study have marked the smoking and chewing  khat 
as risk factor for T2D while sex and tobacco use in 
hepatitis patients tables 1 and 3. Our results agreement 
with [7,21,22]with some risk factors for the 
development of diabetes in hepatitis patients. HCV was 
currently associated with family history of diabetes, 
positively in persons with diabetes and inversely in 
those with IFG, suggesting that family history of 
diabetes may serve as a cofactor for progression from 
HCV-associated IFG to diabetes [21]. Patients with 
DM were significantly older, a higher percentage of 
diabetics reported family history DM compared with 
non-diabetics (54% vs 30%)[7]. The association 
between HCV infection and DM remained highly 
significant after adjustment for age, sex, ethnicity, 
BMI, smoking, alcohol use, corticosteroid use and 
family history of DM(OR = 3.27; 95% CI, 2.01–5.31) 
[22]. We found statically analysis the sex and tobacco 
use as the high risk factors. The distribution of gender, 
family history of diabetes, age and BMI in T2D-
patients with HCV viremia was not statistically 
different from that in T2D-patients with no evidence of 
HCV infection [12] in agreement with our results table 
1 which shown not significantly in T2D 
sociodemographic. The mean age of the DM group was 
higher than that of the HCV-DM group and that there 
were more females in the T2D group than in the HCV- 
DM group [13]. Similar with our results which DM 
group was less 54% and 62% with DM and HCV. 
Conclusions 
The development of DM among hepatitis C and B 
patients lower than prevalence HCV and HBV among 
diabetic patients, but the major significant  in our study 
higher prevalence of HCV in T2D-patients than HBV 
infection, and the predisposed DM to develop in HCV 
infection patient higher than predisposed HCV in 
diabetes patients. 
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